Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlucoTrack Inc GCTK

Healthcare Medical Devices
GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an... see more

Recent & Breaking News (NDAQ:GCTK)

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

GlobeNewswire 2 days ago

GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

GlobeNewswire April 2, 2024

GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY

GlobeNewswire March 12, 2024

GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

GlobeNewswire February 27, 2024

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

GlobeNewswire February 13, 2024

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

GlobeNewswire January 2, 2024

GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

GlobeNewswire November 30, 2023

This stock is ready to capture the lead in the diabetes market

Jonathon Brown November 28, 2023

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

GlobeNewswire November 13, 2023

Glucotrack announces preclinical continuous glucose monitor testing

Jonathon Brown October 12, 2023

GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

GlobeNewswire October 12, 2023

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS

GlobeNewswire August 31, 2023

GLUCOTRACK ANNOUNCES NEW VP OF MARKETING

GlobeNewswire August 28, 2023

Medical device company simplifies continuous glucose monitors

Trevor Abes  August 2, 2023

GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

GlobeNewswire July 25, 2023

Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)

Accesswire April 17, 2023

GlucoTrack Closes $10 Million Underwritten Public Offering of Common Stock

GlobeNewswire April 17, 2023

GlucoTrack's (NASDAQ:GCTK) new $10M underwritten public offering

Coreena Robertson April 13, 2023

GlucoTrack Announces Pricing of $10 Million Underwritten Public Offering of Common Stock

GlobeNewswire April 13, 2023

GlucoTrack Announces Proposed Underwritten Public Offering of Common Stock

GlobeNewswire April 12, 2023